Cardiology Pharmaceuticals

Alnylam’s Promising Heart Failure Treatment

Clinical Trial

Alnylam Pharmaceuticals claimed a major success this week, with its RNAi drug Onpattro achieving the primary endpoint in its high-stakes APOLLO-B study for transthyretin amyloid cardiomyopathy. 

The phase 3 clinical trial became one of the year’s most closely watched studies in biotech after BridgeBio Pharma’s competing treatment failed in a late-stage trial last December. Because Alnylam’s trial was similarly designed, investors worried it would face the same fate. 

Alnylam’s Onpattro is FDA approved to treat polyneuropathy caused by the toxic buildup of misfolded transthyretin protein, a condition called ATTR. Alnylam is seeking to expand Onpattro’s use to treat ATTR cardiomyopathy, or ATTR-CM, which is a leading cause of heart failure. 

In the phase 3 study, 360 adults with ATTR-CM were randomized to receive 0.3 mg/kg of Onpattro or placebo intravenously administered every three weeks over 12 months. Here is what researchers found: 

  • Onpattro takers experienced a significant improvement in a six-minute walk test compared to the placebo group (P=0.016), meeting the trial’s primary goal.
  • Patients also reported improved quality of life compared to the placebo group (P=0.04), meeting a secondary goal.
  • However, treatment did not lead to a statistically significant difference in a composite assessment, which tracked all-cause mortality and frequency of CV events, as well as six-minute walk test scores. 

The Takeaway

Alnylam plans to apply for FDA approval of Onpattro in ATTR-CM in late 2022, setting up a potential launch in 2023. If approved, the drug would compete with Pfizer’s blockbuster tafamidis franchise, which raked in $909M last year in the US alone.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Surgeries & Interventions June 23, 2025

Edwards’ Evoque Might Have More Adverse Events Than Previously Known June 23, 2025

Over a year after becoming the first FDA-approved transcatheter tricuspid valve replacement system, a new JACC study suggests Edwards Lifesciences’ Evoque TTVR system might have some risks that regulators hadn’t previously considered. Searching for more answers about Evoque’s real world risks, researchers pulled data from the FDA’s Manufacturer and User Facility Device Experience (MAUDE) database […]

Cardiology Business June 19, 2025

Lilly Buys Verve, Bringing Gene Editing Mainstream June 19, 2025

Gene editing for heart disease just got a major boost as Eli Lilly acquired Verve Therapeutics and its one-dose cholesterol drugs for up to $1.3B, marking a new path for Verve’s therapies to go mainstream. Part of the acquisition likely stems from Verve’s recent impressive trial results for its PCSK9-blocking treatment, VERVE-102, which lowered LDL-C […]

Cardiac Imaging June 19, 2025

New AI-driven Tool Aids in Mitral Valve Assessment June 19, 2025

By: Jimmy Su, Ph.D. Principal Scientist, Cardiovascular Ultrasound, Philips A new tool, Automated 3D Color Flow Quantification (3D Auto CFQ), removes the reliance on assumptions when quantifying mitral regurgitation and replaces it with a reliable and robust, AI-driven method that delivers precise measurement of mitral valve regurgitant volume (RVol) regardless of orifice shape and size. Eliminating assumptions: Quantification […]

You might also like..

Select All

You're signed up!

It's great to have you as a reader. Check your inbox for a welcome email.

-- The Cardiac Wire Team

You're all set!